Skip to content
DataLookout
Menu

NCT04604067

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 2 years 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jul 30, 2026 to Jan 30, 2029 Show 4 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Study description shortened, about 11 words
    • Site details revised at 1 of 19 sites
  2. Notable Primary completion date: Oct 2025 to Jul 30, 2026v14
  3. Study Identification, Study Status, Oversight, IPDSharingv12
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 19 of 19 sites
    v11
  5. Minor Site details revised at 2 of 19 sitesv10
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Eligibility criteria expanded, about 37 words
    • Primary completion date: Mar 2026 to Oct 2025
    v9
  2. Notable Primary completion date: Mar 2025 to Mar 2026
    • Eligibility criteria expanded, about 55 words
    • Study sites: 17 to 19
    • Study description shortened, about 13 words
    v8
  3. Minor Study sites: 14 to 17v6
  4. Minor Study sites: 12 to 14v5
  5. Minor Start date changed from estimate of Oct 2021 to Jun 25, 2021v4
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 12 of 12 sites
    v3
  7. Notable Start date: Dec 2020 to Oct 2021v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohorts A, C and D: Progression free survival (PFS) according to the Lugano criteria
Timeframe: from registration until the first event as defined in PFS (estimated 2 years)
Cohort B: Complete remission (CR) rate at the end of therapy according to the Lugano criteria
Timeframe: estimated 9 months after registration

Secondary (6)

Adverse events (AEs)
Overall survival (OS)
Progression free survival in cohort B
Complete remission rate in cohorts A, C and D
Overall response rate (ORR)
Show 1 moreShow less
Duration of response (DoR)

Arms and interventions

Arm with 4 cohortsExperimental

Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles. Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline: Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (\>2log10 reduction of ctDNA) results: Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent. Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent. Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total). Follow up: Patients off treatment will be followed for 5 years.

Drugs: Acalabrutinib

Sites

19 sites in 2 countries

Switzerland 16, Italy 3